Mosby's 2014 Nursing Drug Reference (258 page)

BOOK: Mosby's 2014 Nursing Drug Reference
11.23Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

mesalamine, 5-ASA (Rx)

(mez-al′a-meen)

Apriso, Asacol, Asacol HD, Canasa, Lialda, Pentasa, Rowasa Salofalk
, sf Rowasa

Func. class.:
GI antiinflammatory

Chem. class.:
5-Aminosalicylic acid

Do not confuse:
Asacol
/Ansaid/Os-Cal

ACTION:

May diminish inflammation by blocking cyclooxygenase, inhibiting prostaglandin production in colon; local action only

USES:

Mild to moderate active distal ulcerative colitis, proctosigmoiditis, proctitis

Unlabeled uses:
Crohn’s disease

CONTRAINDICATIONS:

Hypersensitivity to this product or salicylates, 5-aminosalicylates

Precautions:
Pregnancy (B), breastfeeding, children, geriatric patients, renal disease, sulfite sensitivity, pyloric stenosis

DOSAGE AND ROUTES
Calculator
Treatment of ulcerative colitis

• Adult:
RECT
60 ml (4 g) at bedtime, retained for 8 hr × 3-6 wk;
DEL REL TAB (Lialda)
2.4-4.8 g/day × 8 wk;
DEL REL TAB (Asacol)
800 mg tid × 6 wk;
CONTROLLED REL CAP (Pentasa)
1 g qid up to 8 wk;
EXT REL
cap
(Apriso)
1500 mg (4 caps) q
AM
daily up to 6 mo,
RECT SUPP
500 mg bid retained for 1-3 hr × 3-6 wk until remission, may increase tid if needed

Maintenance of remission

• Adult:
PO
(del rel tab: Asacol) 800 mg bid or 400 mg qid;
PO
(del rel cap: Apriso) 1500 mg (4 caps) each
AM
;
PO
(del rel tab: Lialda) 2.4 g (2 tabs) daily with meal

Available forms:
Enema 4 g/60 ml (Rowasa, sf Rowasa); ext rel tab 500 mg; ext rel cap 250, 500 mg (Pentasa); 0.375 g (Apriso); del rel tab 400 mg (Asacol), 800 mg (Asacol HD); del rel tab (Lialda) 1.2 g; rectal supp 1000 mg (Canasa)

Administer:
PO route

• 
Swallow tabs whole; do not break, crush, or chew tabs

• 
Lialda:
take with meal

• 
Apriso caps:
take without regard to meals in
AM

Rectal suspension

• 
Product should be given at bedtime, retained until morning (8 hr); empty bowel before insertion, shake well

Rectal suppository

• 
Moisten before insertion; suppository should be retained for 1-3 hr

SIDE EFFECTS

CNS:
Headache, fever, dizziness
, insomnia, asthenia, weakness, fatigue

CV:
Pericarditis, myocarditis, chest pain, palpitations

EENT:
Sore throat, cough, pharyngitis, rhinitis

GI:
Cramps, gas, nausea, diarrhea
, rectal pain, constipation

GU:
Nephrotoxicity, interstitial nephritis

INTEG:
Rash, itching
, acne

SYST:
Flulike symptoms, malaise
, back pain, peripheral edema, leg and joint pain, arthralgia, dysmenorrhea,
anaphylaxis,
acute intolerance syndrome

PHARMACOKINETICS

RECT:
Primarily excreted in feces but some in urine as metabolite; half-life 1 hr, metabolite half-life 5-10 hr

INTERACTIONS

• 
Do not give H
2
blockers with Apriso

Increase:
nephrotoxicity—NSAIDs

Increase:
action, adverse reactions of azaTHIOprine, mercaptopurine

Decrease:
mesalamine absorption—lactulose, antacids

Decrease:
effect of—warfarin

Drug/Lab Test

Increase:
AST, ALT, alk phos, LDH, GGTP, amylase, lipase

NURSING CONSIDERATIONS
Assess:

• 
Allergy to salicylates, sulfonamides;
if allergic reactions occur, discontinue product

• 
Renal studies: BUN, creatinine before, periodically during treatment; renal toxicity may occur

• 
Bowel disorders:
cramps, gas, nausea, diarrhea, rectal pain; if severe, product should be discontinued

Evaluate:

• 
Therapeutic response: absence of pain, bleeding from GI tract, decrease in number of diarrhea stools

Teach patient/family:

• 
That usual course of therapy is 3-6 wk

• 
To shake bottle well (rectal susp)

• 
About method of rectal administration

• 
To inform prescriber of GI symptoms

• 
To report abdominal cramping, pain, diarrhea with blood, headache, fever, rash, chest pain; product should be discontinued

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

metformin (Rx)

(met-for′min)

Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet

Func. class.:
Antidiabetic, oral

Chem. class.:
Biguanide

ACTION:

Inhibits hepatic glucose production and increases sensitivity of peripheral tissue to insulin

USES:

Type 2 diabetes mellitus

Unlabeled uses:
Precocious puberty or early-normal onset of puberty to delay menarche; polycystic ovary syndrome, infertility

CONTRAINDICATIONS:

Hypersensitivity; hepatic disease; creatinine ≥1.5 mg/ml (males), ≥1.4 (females); alcoholism; cardiopulmonary disease; acidemia; acute MI; cardiogenic shock; diabetic ketoacidosis; metabolic acidosis

 

Black Box Warning:

History of lactic acidosis

Precautions:
Pregnancy (B), breastfeeding, geriatric patients, previous hypersensitivity, thyroid disease, CHF, type 1 diabetes mellitus

DOSAGE AND ROUTES
Calculator
Type 2 diabetes mellitus

• Adult:
PO
500 mg bid or 850 mg/day initially then 500 mg weekly or 850 mg q2wk up to 2000 mg/day in divided doses with morning meal, with dosage increased every other wk, max 2550 mg/day,
EXT REL
(Glucophage XR) 500 mg daily with evening meal, may increase by 500 mg per wk, max 2000 mg/day; (Glumetza) 1000 mg daily with food, preferably with
PM
meal, may increase by 500 mg per wk, max 2000 mg daily; (Fortamet) 500-1000 mg daily with
PM
meal, may increase by 500 mg per wk, max 2550 mg daily; regular rel or oral sol 2000-2500 mg/day for ext rel tab, depending on formulation

• Geriatric:
PO
Use lowest effective dose

To delay early menarche and to prolong pubertal growth with early onset of puberty (unlabeled)

• Child 8-9 yr:
PO
825 mg/day with
PM
meal

To delay clinical puberty and early menarche in precocious puberty (unlabeled)

• Child >6 yr:
PO
425 mg/day with
PM
meal

Polycystic ovary syndrome/infertility related to hyperinsulinemia secondary to polycystic ovary syndrome (unlabeled)

• Adult (female):
PO
500 mg tid

Available forms:
Tabs 500, 850, 1000 mg; ext rel tab 500, 850, 1000 mg; oral sol 500 mg/5 ml

Administer:
PO route

• 
Immediate rel product:
twice a day given with meals to decrease GI upset, and provide the best absorption; immediate rel tabs crushed, mixed with meal, fluids for patients with difficulty swallowing

• 
Ext rel product
may also be taken as single dose; titrate slowly to therapeutic response, side effect tolerance

• 
Ext rel tabs: do not chew, break, crush

SIDE EFFECTS

CNS:
Headache, weakness, dizziness, drowsiness
, tinnitus, fatigue, vertigo,
agitation

CV:
Heart failure

ENDO:
Lactic acidosis,
hypoglycemia

GI:
Nausea, vomiting, diarrhea
, heartburn, anorexia, metallic taste

HEMA:
Thrombocytopenia,
decreased vit B
12
levels

INTEG:
Rash

PHARMACOKINETICS

Excreted by kidneys unchanged 35%-50%, half-life 1½-5 hr, terminal 6-20 hr, peak 1-3 hr

INTERACTIONS

• 
Do not give with radiologic contrast media; may cause renal failure

• 
Do not use with dofetilide; may cause lactic acidosis

Increase:
metformin level—cimetidine, digoxin, morphine, procainamide, quiNIDine, ranitidine, triamterene, vancomycin

Increase:
hyperglycemia—calcium channel blockers, corticosteroids, estrogens, oral contraceptives, phenothiazines, sympathomimetics, diuretics, phenytoin, β-blockers

Drug/Herb

Increase:
hyperglycemia—glucosamine

Increase:
hypoglycemia—garlic, green tea, horse chestnut

Drug/Lab Test

Decrease:
vit B12

NURSING CONSIDERATIONS
Assess:

• 
Hypoglycemic reactions
(sweating, weakness, dizziness, anxiety, tremors, hunger); hyperglycemic reactions soon after meals; these occur rarely with product, may occur when product combined with sulfonylureas

• 
CBC (baseline, q3mo) during treatment; check LFTs periodically, AST, LDH, renal studies: BUN, creatinine during treatment; glucose, A1c; folic acid, vit B
12
q1-2yr

• 
Surgery:
product should be discontinued temporarily for surgical procedures when patient is NPO or if contrast media is used, resume when patient is eating

 

Black Box Warning:

Lactic acidosis:
malaise, myalgia, abdominal distress; risk increases with age, poor renal function; monitor electrolytes, lactate, pyruvate, blood pH, ketones, glucose; suspect in any diabetic patient with metabolic acidosis, with ketoacidosis; immediately stop product if hypoxemia or significant renal dysfunction occurs

Perform/provide:

• 
Conversion from other oral hypoglycemic agents; change may be made without gradual dosage change; monitor serum glucose, urine ketones tid during conversion

• 
Storage in tight container in cool environment

Evaluate:

• 
Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; blood glucose, A1c at normal level

Teach patient/family:

 

Black Box Warning:

Lactic acidosis:
hyperventilation, fatigue, malaise, chills, myalgia, somnolence; to notify prescriber immediately; stop product

• 
To regularly self-monitor blood glucose with blood-glucose meter

• 
About symptoms of hypo/hyperglycemia, what to do about each (rare)

• 
That product must be continued on daily basis; about consequences of discontinuing product abruptly

• 
To avoid OTC medications, alcohol unless approved by prescriber

• 
That diabetes is a lifelong illness; that product is not a cure, only controls symptoms

• 
To carry emergency ID and glucagon emergency kit

• 
That Glucophage XR tab may appear in stool

• 
To take with meals, not to break, crush, chew ext rel product

• 
About signs, symptoms of hypo/hyperglycemic reactions

Other books

Priced to Move by Ginny Aiken
The Trouble with Mark Hopper by Elissa Brent Weissman
Any Witch Way by Annastaysia Savage
Hasty Wedding by Mignon G. Eberhart
The Vampire and the Virgin by Kerrelyn Sparks
A Hat Full Of Sky by Terry Pratchett
Breanna by Karen Nichols
The Guardian Mist by Susan Stoker
La lista de mis deseos by Grégoire Delacourt
Healer by Bonnie Watson